ArticleOncoimmunology2026
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) produced by melanoma cells (MTEX) carry ecto-nucleotidases, CD39/CD73, on their surface membrane, produce adenosine (ADO), and deliver it to immune recipient cells, inducing immune suppression. Based on studies of MTEX from melanoma cell lines, we hypothesized that MTEX are the major producers of ADO in cancer patients' plasma, which contains a variable mix of MTEX and NTEX. To test this hypothesis, EVs were isolated from the plasma of melanoma patients with no evidence of disease (NED) or with metastatic disease at phlebotomy, and MTEX were separated from EVs produced by non-malignant cells (NTEX) by immune capture using anti-CSPG4 mAbs. The purinergic activity of CD39/CD73 in total plasma EVs and NTEX was measured by high-pressure liquid chromatography with fluorescence detection, and that in MTEX was calculated. Unexpectedly, NTEX showed higher levels of purinergic activity than MTEX. While higher purinergic activity of NTEX
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.